Today's radiology community depends heavily on cutting-edge diagnostic and
therapeutic medical devices to serve patients. These products are regulated
by the U.S. Food and Drug Administration (FDA) under a system that grants
marketing approval for only those indications for which the safety and effe
ctiveness have been established. Although this complex system is the result
of a societal decision to ensure device safety and effectiveness, it has t
he potential to delay product marketing and impede innovation. Medical devi
ce regulation recently has undergone major changes with the enactment of th
e Food and Drug Administration Modernization Act of 1997 (FDAMA), legislati
on that is intended to increase system efficiency while retaining the requi
rement of safety and effectiveness. However, many of the envisioned improve
ments cannot occur without cooperative interaction between stakeholders in
the device development process, including the FDA and the clinical medicine
community. The radiology field must continue to build on its strong histor
y of productive dialogue with the FDA to transform the legislative vision o
f FDAMA into regulatory reality. Such action will ensure timely access to t
he new device technologies that are necessary for the growth of our special
ty and the effective care of our patients.